Page last updated: 2024-08-24

aptiganel and 6-(1h-imidazol-1-yl)-7-nitro-2,3(1h,4h)-quinoxalinedione

aptiganel has been researched along with 6-(1h-imidazol-1-yl)-7-nitro-2,3(1h,4h)-quinoxalinedione in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kawasaki-Yatsugi, S; Shimizu-Sasamata, M; Yamaguchi, T; Yatsugi, S	1

Other Studies

1 other study(ies) available for aptiganel and 6-(1h-imidazol-1-yl)-7-nitro-2,3(1h,4h)-quinoxalinedione

Article	Year
Delayed treatment with YM90K, an AMPA receptor antagonist, protects against ischaemic damage after middle cerebral artery occlusion in rats. The Journal of pharmacy and pharmacology, 1998, Volume: 50, Issue:8 Topics: Animals; Brain Ischemia; Cerebral Arteries; Dose-Response Relationship, Drug; Guanidines; Injections, Intravenous; Male; Neuroprotective Agents; Quinoxalines; Rats; Rats, Inbred F344; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Time Factors	1998

Article

Year

Delayed treatment with YM90K, an AMPA receptor antagonist, protects against ischaemic damage after middle cerebral artery occlusion in rats.

The Journal of pharmacy and pharmacology, 1998, Volume: 50, Issue:8

Topics: Animals; Brain Ischemia; Cerebral Arteries; Dose-Response Relationship, Drug; Guanidines; Injections, Intravenous; Male; Neuroprotective Agents; Quinoxalines; Rats; Rats, Inbred F344; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Time Factors

1998